K1-70 - A Phase I, Single Ascending Intramuscular Dose, Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study in Subjects With Graves' Disease

Trial Profile

K1-70 - A Phase I, Single Ascending Intramuscular Dose, Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study in Subjects With Graves' Disease

Recruiting
Phase of Trial: Phase I

Latest Information Update: 15 Dec 2017

At a glance

  • Drugs K1 70 (Primary)
  • Indications Graves' disease
  • Focus Adverse reactions; First in man
  • Sponsors AV7
  • Most Recent Events

    • 12 Dec 2017 Planned End Date changed from 1 Apr 2017 to 1 Feb 2020.
    • 12 Dec 2017 Planned primary completion date changed from 1 Apr 2017 to 1 Feb 2020.
    • 28 Sep 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top